TY - JOUR
T1 - Ligand efficiency outperforms pIC50 on both 2D MLR and 3D CoMFA models
T2 - A case study on AR antagonists
AU - Li, Jiazhong
AU - Bai, Fang
AU - Liu, Huanxiang
AU - Gramatica, Paola
N1 - Publisher Copyright:
© 2015 John Wiley & Sons A/S.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - The concept of ligand efficiency is defined as biological activity in each molecular size and is widely accepted throughout the drug design community. Among different LE indices, surface efficiency index (SEI) was reported to be the best one in support vector machine modeling, much better than the generally and traditionally used end-point pIC50. In this study, 2D multiple linear regression and 3D comparative molecular field analysis methods are employed to investigate the structure-activity relationships of a series of androgen receptor antagonists, using pIC50 and SEI as dependent variables to verify the influence of using different kinds of end-points. The obtained results suggest that SEI outperforms pIC50 on both MLR and CoMFA models with higher stability and predictive ability. After analyzing the characteristics of the two dependent variables SEI and pIC50, we deduce that the superiority of SEI maybe lie in that SEI could reflect the relationship between molecular structures and corresponding bioactivities, in nature, better than pIC50. This study indicates that SEI could be a more rational parameter to be optimized in the drug discovery process than pIC50. We expanded the application of the ligand efficiency SEI to MLR and CoMFA modeling to investigate the relationships between the hydantoin derivatives and AR antagonist activities. The obtained results indicate that the SEI-based models outperform the pIC50-based models with higher stability, robustness, and predictive abilities. We put forward our opinion that SEI can incarnate the relationships between bioactivities and molecular structures better than pIC50, in nature. SEI could be a more rational parameter to be optimized in the drug discovery.
AB - The concept of ligand efficiency is defined as biological activity in each molecular size and is widely accepted throughout the drug design community. Among different LE indices, surface efficiency index (SEI) was reported to be the best one in support vector machine modeling, much better than the generally and traditionally used end-point pIC50. In this study, 2D multiple linear regression and 3D comparative molecular field analysis methods are employed to investigate the structure-activity relationships of a series of androgen receptor antagonists, using pIC50 and SEI as dependent variables to verify the influence of using different kinds of end-points. The obtained results suggest that SEI outperforms pIC50 on both MLR and CoMFA models with higher stability and predictive ability. After analyzing the characteristics of the two dependent variables SEI and pIC50, we deduce that the superiority of SEI maybe lie in that SEI could reflect the relationship between molecular structures and corresponding bioactivities, in nature, better than pIC50. This study indicates that SEI could be a more rational parameter to be optimized in the drug discovery process than pIC50. We expanded the application of the ligand efficiency SEI to MLR and CoMFA modeling to investigate the relationships between the hydantoin derivatives and AR antagonist activities. The obtained results indicate that the SEI-based models outperform the pIC50-based models with higher stability, robustness, and predictive abilities. We put forward our opinion that SEI can incarnate the relationships between bioactivities and molecular structures better than pIC50, in nature. SEI could be a more rational parameter to be optimized in the drug discovery.
KW - androgen receptor antagonist
KW - comparative molecular field analysis
KW - ligand efficiency
KW - multiple linear regression
KW - surface efficiency index
UR - http://www.scopus.com/inward/record.url?scp=84956584689&partnerID=8YFLogxK
U2 - 10.1111/cbdd.12619
DO - 10.1111/cbdd.12619
M3 - Article
C2 - 26198098
AN - SCOPUS:84956584689
SN - 1747-0277
VL - 86
SP - 1501
EP - 1517
JO - Chemical Biology and Drug Design
JF - Chemical Biology and Drug Design
IS - 6
ER -